

Current Effective Date: 12/29/24

Status: Approved

Reviewed by Medical Policy Subcommittee: 12/1/23, 12/29/24

Reviewed Dates: 14/14/23, 12/3/24

### **INSTRUCTIONS FOR USE DISCLAIMER:**

SummaCare posts policies relating to coverage and medical necessity issues to assist members and providers in administering member benefits. These policies do not constitute a contract or agreement between SummaCare and any member or provider. The policies are guidelines only and are intended to assist members and providers with coverage issues. SummaCare is not a health care provider, does not provide or assist with health care services or treatment, and does not make guarantees as to the effectiveness of treatment administered by providers. The treatment of members is the sole responsibility of the treating provider, who is not an employee of SummaCare, but is an independent contractor in private practice. The policies posted to this site may be updated and are subject to change without prior notice to members or providers.

Medical policies in conjunction with other nationally recognized standards of care are used to make medical coverage decisions.

### **Continuous Glucose Monitoring System Policy Indication/Usage:**

A continuous glucose monitoring system (CGMS), measures glucose levels in interstitial fluid at programmable intervals up to 90 days. Minimally invasive devices use a small wire-like sensor inserted just under the skin to read glucose levels in the interstitial fluid, which then transmits this information to a monitor/receiver. When used in combination with a glucose meter, CGM information can help people with diabetes detect when values are approaching dangerously high or dangerously low levels. If reviewed retrospectively by the physician, the measurements can guide adjustments to therapy, with the goal of improving overall glycemic control. The glucose measurements provided during continuous monitoring are not intended to replace standard selfmonitoring of blood glucose (SMBG) obtained using finger-stick blood samples (Hayes, 2016) (CMS, 2022)

### **Medical Indications for Authorization**

#### **Commercial Members**

### **Short-term Use**

Intermittent, short-term, (72 hours to 1 week) use of an FDA approved continuous glucose monitoring device as an adjunct to standard of care is considered medically necessary in the care of patients with diabetes, when the following criteria are met:

- For insulin dependent patients with Type 1 or Type 2 diabetes with inadequate glycemic control despite compliance with frequent self-monitoring and conventional insulin adjustment. *AND*
- Fasting hyperglycemia (>150 mg/dl) or recurring episodes of severe hypoglycemia

### **Long-term Use**

Long-term use of continuous glucose monitoring with an FDA-approved device is considered medically necessary for any of the following:

All patients regardless of age with Type 1 Type 2 or gestational diabetes who meet the following criteria:

- Member or caregiver must have an understanding of the pump technology and motivation to use it correctly and consistently
- Inadequate glycemic control
- Insulin injections are required 3 or more times per day or a medically necessary insulin pump is used for maintenance of blood sugar control

### **OR**

Member has a history of problematic hypoglycemia with documentation of at least one of:

- Recurrent (more than one) level 2 hypoglycemic events
- Recurrent (more than one) level 2 hypoglycemic events (glucose <54mg/dL that persist despite multiple (more than one) attempts to adjust medication(s) and/or
- modify the diabetes treatment plan; **OR**
  - A history of one level 3 hypoglycemic event (glucose <54mg/dL) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia

### **Medicare Members**

CMS CGS LCD ID L38662 Implantable Continuous Glucose Monitors (I-CGM)

### **Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity**

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

## **History/Background and/or General Information Covered Indications**

I-CGMs are class III medical devices that require premarket approval by the FDA. In order to be considered reasonable and necessary, the FDA approved indication must include use as a therapeutic CGM.<sup>1</sup> The FDA recently approved expanding the indications of an implantable CGM product to replace finger stick blood glucose measurements for diabetes treatment decisions.

Therapeutic I-CGMs are considered reasonable and necessary by Medicare when all of the following coverage criteria (1-4) are met:

1. The beneficiary has diabetes mellitus (Refer to the ICD-10 code list in the LCD-related Policy Article for applicable diagnoses); and,
2. The beneficiary's treating practitioner has concluded that the beneficiary (or beneficiary's caregiver) has sufficient training using the I-CGM prescribed as evidenced by providing a prescription; and,
3. The I-CGM is prescribed in accordance with its FDA indications for use; and,
4. The beneficiary for whom a I- CGM is being prescribed, to improve glycemic control, meets at least one of the criteria below:
  - The beneficiary is insulin-treated; or,
  - The beneficiary has a history of problematic hypoglycemia with documentation of at least one of the following:
    - Recurrent (more than one) level 2 hypoglycemic events (glucose <54mg/dL (3.0mmol/L)) that persist despite multiple (more than one) attempts to adjust medication(s) and/or modify the diabetes treatment plan; or,
    - A history of one level 3 hypoglycemic event (glucose <54mg/dL (3.0mmol/L)) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia

## **CGM Continued Coverage**

Every six (6) months following the initial prescription of the CGM, the treating practitioner conducts an in-person or Medicare-approved telehealth visit with the beneficiary to document adherence to their CGM regimen and diabetes treatment plan.

## **Limitations**

I-CGM devices will not be considered reasonable and necessary for short-term (72 hours to 1 week) diagnostic use.

## **Exception**

For those beneficiaries who have previously met the coverage criteria for a non-implantable therapeutic continuous glucose monitor through the Medicare DME benefit and subsequently choose to switch to

the implantable device, they may do so with a provider order. However, all other coverage criteria above must be fulfilled in order for Medicare payment.

### **Limitations**

Long-term use of continuous glucose monitors for individuals with persons with type 2 diabetes not using intensive insulin regimens is considered experimental

I-CGM devices will not be considered reasonable and necessary for short-term (72 hours to 1 week) diagnostic use.

The American Diabetes Society recommends against using continuous glucose monitoring in a hospital setting (Cefalu, 2017)

### **Exception**

For those beneficiaries who have previously met the coverage criteria for a non-implantable therapeutic continuous glucose monitor through the Medicare DME benefit and subsequently choose to switch to the implantable device, they may do so with a provider order. However, all other coverage criteria above must be fulfilled in order for Medicare payment.

### **For information on FDA CGMs, refer to the following websites:**

Product code LZG: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm> Product code MDS: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm>

### **Coverage Decisions**

Coverage decisions made per CMS Guidelines, Hayes Research and industry standards research

### **Plans Covered By This Policy**

Commercial and Medicare

Self-funded Commercial groups refer to plan document for coverage

### **Sources Reviewed**

Abbott Diabetes Care. Freestyle Navigator Continuous Glucose Monitoring System. User Guide. 2010.

Available at: [http://abbottdiabetescare.co.uk/images/uploads/documents/FSNv1.5\\_ART20775-001\\_RevA.pdf](http://abbottdiabetescare.co.uk/images/uploads/documents/FSNv1.5_ART20775-001_RevA.pdf). Accessed August 3, 2015

Battelino T, Conget I, Olsen B, et al.; SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. *Diabetologia*. 2012;55 (12):3155-3162.

Cefalu, W. T. (2017). American Diabetes Association Standards of Medical Care in Diabetes 2017. s121.

DexCom Inc. DexCom G4 Continuous Glucose Monitoring System. User's Guide. 2013. Available at:  
<http://www.dexcom.com/sites/dexcom.com/files/dexcomg4/docs/dexcomG4UsersGuideEnglishmmol24hr.pdf>.

(FDA), F. a. (2016). FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decisions.

Hayes. (2016, 8 23). Retrieved 6 29, 2017, from Continuous Glucose Monitoring Systems:  
[https://www.hayesinc.com/subscribers/displaySubscriberArticle.do?articleId=1882&searchStore=%24search\\_type%3Dall%24icd%3D%24keywords%3Dcontinuous%2Cglucose%2Cmonitoring%24status%3Dall%24page%3D1%24from\\_date%3D%24to\\_date%3D%24report\\_type\\_options%3D%24techn](https://www.hayesinc.com/subscribers/displaySubscriberArticle.do?articleId=1882&searchStore=%24search_type%3Dall%24icd%3D%24keywords%3Dcontinuous%2Cglucose%2Cmonitoring%24status%3Dall%24page%3D1%24from_date%3D%24to_date%3D%24report_type_options%3D%24techn)

Klonoff DC, Buckingham B, Christiansen JS, et al.; Endocrine Society. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2010;96 (10):2968- 2979.

Raccach D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. *Diabetes Care*. 2009;32 (12):2245-2250.

Tildesley HD, Wright AM, Chan JH, et al. A comparison of internet monitoring with continuous glucose monitoring in insulin-requiring type 2 diabetes mellitus. *Can J Diabetes*. 2013;37 (5):305308.

Voormolen DN, DeVries JH, Evers IM, Mol BW, Franx A. The efficacy and effectiveness of continuous glucose monitoring during pregnancy: a systematic review. *Obstet Gynecol Surv*. 2013;68 (11):753-763.